Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) Shares Outstanding (Weighted Average) (2023 - 2025)

Historic Shares Outstanding (Weighted Average) for CG Oncology (CGON) over the last 3 years, with Q3 2025 value amounting to $76.7 million.

  • CG Oncology's Shares Outstanding (Weighted Average) rose 1427.68% to $76.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $76.7 million, marking a year-over-year increase of 1427.68%. This contributed to the annual value of $62.5 million for FY2024, which is 134303.14% up from last year.
  • As of Q3 2025, CG Oncology's Shares Outstanding (Weighted Average) stood at $76.7 million, which was up 1427.68% from $76.2 million recorded in Q2 2025.
  • Over the past 5 years, CG Oncology's Shares Outstanding (Weighted Average) peaked at $76.7 million during Q3 2025, and registered a low of $3.9 million during Q1 2023.
  • Its 3-year average for Shares Outstanding (Weighted Average) is $44.5 million, with a median of $62.5 million in 2024.
  • Per our database at Business Quant, CG Oncology's Shares Outstanding (Weighted Average) soared by 160088.78% in 2024 and then surged by 1427.68% in 2025.
  • CG Oncology's Shares Outstanding (Weighted Average) (Quarter) stood at $4.3 million in 2023, then surged by 1343.03% to $62.5 million in 2024, then increased by 22.77% to $76.7 million in 2025.
  • Its last three reported values are $76.7 million in Q3 2025, $76.2 million for Q2 2025, and $76.2 million during Q1 2025.